Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial...

Area of Science:

• Cardiovascular Medicine
• Hematology
• Immunology

Background:

• The REVIVAL-2 trial investigated granulocyte-colony stimulating factor (G-CSF) in patients with acute myocardial infarction (AMI).
• This substudy focused on G-CSF's effects on systemic inflammation, coagulation, and platelet activation post-AMI.
• Patients received either G-CSF or placebo after mechanical reperfusion.

Purpose of the Study:

• To evaluate the impact of G-CSF on inflammatory markers, coagulation activation, and platelet activation in AMI patients.
• To determine if G-CSF influences systemic inflammatory and procoagulant responses.
• To assess G-CSF's effect on platelet activation markers.

Main Methods:

• Prospective, randomized, double-blind, placebo-controlled substudy.
• Measurement of circulating cytokines (IL-1ß, IL-6, IL-8, IL-10, IL-12, TNF-α) and C-reactive protein (CRP).
• Assessment of coagulation activation via prothrombin fragment F1+2 and Tissue Factor activity.
• Flow cytometry analysis of platelet activation markers (PAC-1, P-selectin, CD40L).

Main Results:

• G-CSF administration led to significantly elevated TNF-α and CRP levels compared to placebo after 5 days.
• No significant differences were observed in other measured cytokines (IL-1ß, IL-6, IL-8, IL-10, IL-12) between groups.
• Circulating prothrombin fragments F1+2, Tissue Factor activity, and platelet activation markers remained comparable in both G-CSF and placebo groups.

Conclusions:

• G-CSF treatment in AMI patients is associated with increased pro-inflammatory markers TNF-α and CRP.
• G-CSF did not induce systemic coagulation activation in this patient cohort.
• Platelet activation was not significantly affected by G-CSF treatment in AMI patients.